Pascal Soriot
Directeur Général chez ASTRAZENECA PLC
Fortune : 42 M $ au 31/03/2025
Profil
Actuellement, Pascal Soriot est Chief Executive Officer & Executive Director chez AstraZeneca Plc et président d'AstraZeneca AB (une filiale d'AstraZeneca Plc). Il est également membre du conseil d'administration de Pharmaceutical Research & Manufacturers of America et d'Acerta Pharma BV. Pascal Soriot a précédemment occupé les fonctions de directeur des ventes de district chez Roussel NZ Ltd, de directeur et de directeur général du groupe Roche chez Genentech, Inc, de directeur des opérations chez Roche Pharmaceuticals, Inc, de directeur des opérations chez Sanofi-Aventis U.S. LLC et de vice-président pour l'Asie-Pacifique chez Hoechst Marion Rousel JP. Il est titulaire d'un MBA de l'École des Hautes Études Commerciales de Paris et d'un doctorat de l'École Nationale Vtrinaire d'Alfort.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ASTRAZENECA PLC 0,02% | 05/03/2025 | 287 466 ( 0,02% ) | 42 M $ | 31/03/2025 |
Dernières actualités sur Pascal Soriot
Postes actifs de Pascal Soriot
| Sociétés | Poste | Début |
|---|---|---|
| ASTRAZENECA PLC | Directeur Général | 01/10/2012 |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America BiotechnologyHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Directeur/Membre du Conseil | - |
AstraZeneca Österreich GmbH | Directeur Général | - |
AstraZeneca UK Ltd.
 AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. | Directeur Général | - |
AstraZeneca Holding GmbH
 AstraZeneca Holding GmbH Financial ConglomeratesFinance Part of AstraZeneca PLC, AstraZeneca Holding GmbH functions as an investment holding German company. The company is based in Wedel, Germany. The CEO of the company is Hans Sijbesma. | Directeur Général | - |
AstraZeneca Pharmaceuticals LP
 AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE. | Directeur Général | - |
Acerta Pharma BV
 Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | Directeur/Membre du Conseil | - |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Président | - |
AstraZeneca Colombia SAS | Directeur Général | 01/10/2012 |
Anciens postes connus de Pascal Soriot
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░ ░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ ░░░░ | ░░░░░ ░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Pascal Soriot
École des Hautes Études Commerciales de Paris | Masters Business Admin |
École Nationale Vétérinaire d'Alfort | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CHUGAI PHARMACEUTICAL CO., LTD. | Health Technology |
| ASTRAZENECA PLC | Health Technology |
| CSL LIMITED | Health Technology |
| Entreprise privées | 14 |
|---|---|
Genentech, Inc.
 Genentech, Inc. Pharmaceuticals: MajorHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Roussel NZ Ltd. | |
Hoechst Marion Rousel JP | Commercial Services |
Sanofi-Aventis U.S. LLC
 Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Health Technology |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Commercial Services |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America BiotechnologyHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Health Technology |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE. | Health Technology |
AstraZeneca Holding GmbH
AstraZeneca Holding GmbH Financial ConglomeratesFinance Part of AstraZeneca PLC, AstraZeneca Holding GmbH functions as an investment holding German company. The company is based in Wedel, Germany. The CEO of the company is Hans Sijbesma. | Finance |
AstraZeneca UK Ltd.
AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. | Commercial Services |
AstraZeneca Österreich GmbH | Health Technology |
AstraZeneca Colombia SAS |
